ABOUT ADJUVATIS
Dynamic Biotechnology Company
Founded in December 2013, Adjuvatis specializes in the development, manufacturing and formulation of an innovative biocompatible delivery system, called i-Particles®.
Based on fully metabolizable particles, this technology was initially developed by a joint research unit involving both the French National Center for Scientific Research (CNRS) and bioMérieux company, a global leader in in vitro diagnostics. Ten years of development and international evaluation raised interests and promising prospects in many healthcare fields and led to the creation of Adjuvatis.
From R&D to production, Adjuvatis is operating services for Active Pharmaceutical Ingredients (APIs) and antigens formulation in the fields of vaccines, antibody generation and drug delivery (for cosmetics, dermatology, oncology and more). To fulfill the formulation development, Adjuvatis provides analytical services for customers’ formulations and colloidal technologies. Backed by a robust and quality-oriented development process, our company also proposes a wide variety of i-Particles®-based products.
Our Mission
Providing high quality formulations to improve pharmaceuticals
Built around biosafety concern and safe-by-design concept, Adjuvatis is committed in promoting innovative and safe solutions to improve customer’s pharmaceuticals. Adjuvatis’ i-Particles® provide improvements about healthcare, cost-effectiveness and quality aspects related to three main fields.
VACCINES
Increase immunogenicity, insure biosafety.
i-Particles® support the development of more efficient and safer vaccines and stands as a new class adjuvant.
ANTIBODY GENERATION
Improve cost-effectiveness, quality and productivity.
Our particles act both as a carrier and an amplifier reducing the quantity of costly and unstable antigens while allowing antibodies production with high affinity.
DRUG DELIVERY
Develop patient-friendly formulation, improve efficacy.
i-Particles® insure hydrophobic molecules solubilization, protection and sustained delivery. Our technology aims to overstep pharmaceutical development barriers, proposes new route of administration and increases product life cycle.
technological innovation center
Adjuvatis benefits from a unique environment
At the heart of the Biodistrict Lyon Gerland (France) which brings together world leaders in Life Sciences, surrounded by academic institutions and companies .
MEET OUR TEAM
A broad spectrum of expertise dedicated to your product development
Supported by a referent advisory board and external experts, Adjuvatis team gathers expertise in chemistry, biology, pharmaceutical sciences, manufacturing and partnering. Working collaboratively, we are committed to innovation for your therapeutic product development. To insure partners and customers satisfaction, Adjuvatis implements a quality-dedicated way of working integrating both skills and experience. Adjuvatis provides cutting-edge services for formulation development of customers’ biopharmaceuticals.
Charlotte PRIMARD
PhD - CEO
Bernard VERRIER
PhD, Co-Founder - Scientific Referent
Bernard MANDRAND
PhD, Co-founder - Senior Consultant
David DA COSTA
MSc - Research Engineer
Maxime DZIKOWSKI
MSc - Manufacturing & Quality Control
NETWORK
Our privileged partners and collaborative projects
From extending our technological network to supporting innovation, Adjuvatis scientific partners widen our panel of expertise and contribute with us to strive for excellence. To explore licensing opportunities, collaborative researches, or commercial partnerships, feel free to contact us.
Partnering Projects
European and national innovative programs
European Innovative Training Network DRIVE (funding H2020) 2017-2021 - Driving next generation autophagy researchers towards translation
15 beneficiaries including Adjuvatis,
20 Partners organisation.
National project, ASIO (funding ANR) 2014-2018 - Advanced Skin Immunity by omics analysis
Partners
Adjuvatis
CEA/list DM2I/LADIS
IMABIOTECH ImaBiotech SAS
INSERM 1135 Cimi-Paris Institut National de la Santé et de la Recherche Medicale
PRISM Laboratoire de Spectrométrie de Masse Biologique, Fondamentale et Appliquée, Université Lille1
European project, FluNanoAir (funding EuroNanoMed 3) 2016-2019 - Design of Human Influenza vaccines using multifunctional micelles harnessing innate immunity
Partners
Plana Prades, Fundació Clínic per la Recerca Biomèdica (FCRB), Montserrat, Spain
Primard Charlotte, Adjuvatis France
Cox Rebecca, University of Bergen, Norway
Le Grand Roger, Commissariat à l’Energie Atomique (CEA), France.
National project, PaNaCée (funding ANR and DGA, French army) 2014-2017 - Biodegradable and bioactive nanostructures for functional reconstruction of cutaneous wound
Partners
Adjuvatis
INSERM 1135 Cimi-Paris Institut National de la Santé et de la Recherche Medicale
IRBA Institut de recherche biomédicale des armées
LBTI – CNRS Laboratoire de Biologie Tissulaire et Ingénierie Thérapeutique
